Daniela Magalhães

Jan 15, 2025 | estadao.com.br | Daniela Magalhães

A alta litigiosidade no Brasil é um problema coletivo e crescente que desafia a eficiência e a credibilidade do sistema judiciário. Em razão de inúmeros fatores, inclusive da tecnologia, atualmente, 83 milhões de processos estão em tramitação nos tribunais do país. É como se, a cada três brasileiros, um estivesse com ação na Justiça. A complexidade de lidar com o excesso de litígio prejudica o andamento das ações legítimas e compromete a efetiva prestação jurisdicional.

Jul 19, 2024 | mdpi.com | Daniela Magalhães |Ricardo Goncalves |Cristina V. Rodrigues |Helena Rocha

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Jun 18, 2024 | psychiatrist.com | Filipe Martinho |Daniela Magalhães |Tiago F. Ferreira |Rita Felício

AbstractObjective: To review the literature on the neurobiological mechanisms of obsessive-compulsive symptoms (OCS) in people with dementia. Data Sources: MEDLINE/PubMed, CENTRAL, and PsycNet databases were searched from inception to March 2023. Study Selection: Original studies of any methodology with newly published data on the neurobiological underpinnings of OCS in patients with dementia, regardless of patient age or comorbidity and publication year, were included.

Mar 2, 2024 | onlinelibrary.wiley.com | Daniela Magalhães |Hugo Rafael |Miguel Farinha-Ferreira |Mariana Neuparth-Sottomayor

aCSF artificial cerebral spinal fluid CD86 cluster of differentiation 86 CMS chronic mild stress CRP C-reactive protein DALY disability-adjusted life year EPM elevated plus maze FST forced swim test GAPDH glyceraldehyde 3-phosphate dehydrogenase GFAP glial fibrillary acidic protein HPA axis hypothalamic–pituitary–adrenal axis Iba1 ionized calcium-binding adaptor molecule 1 IFNα interferon α IL-10 interleukin 10 IL-1β interleukin 1β IL-4 interleukin 4 IL-6 interleukin 6 LPS lipopolysaccharide...

Feb 9, 2024 | onlinelibrary.wiley.com | Daniela Magalhães |Nicolas A. Stewart |Myrthe Mampay |Sara O. Rolle

1 INTRODUCTION FTY720, also known as fingolimod, was approved in 2010 by the US Food and Drug Administration (FDA) and became the first oral treatment for relapsing–remitting multiple sclerosis (MS). It is a synthetic compound based on a sphingosine-like fungal metabolite known as ISP-1 (myriocin; 2S-amino-3R,4R-dihydroxy-2-(hydroxymethyl)-14-oxo-6E-eicosenoic acid) and is marketed and sold under the brand name, Gilenya.